Q1 Earnings Estimate for Geron Issued By Leerink Partnrs

Key Points

• Leerink Partners forecasts Geron Corporation's Q1 2026 earnings per share (EPS) at ($0.03), while the full-year earnings estimate stands at ($0.25) per share.
• Geron reported Q2 earnings of ($0.02) EPS, exceeding analysts' expectations, with revenue growing by 5455.6% year-over-year to $49.04 million.
• Institutional ownership of Geron stock is significant, with 73.71% of shares held by institutional investors and hedge funds.

Geron Corporation (NASDAQ:GERN - Free Report) - Leerink Partnrs issued their Q1 2026 EPS estimates for Geron in a report issued on Tuesday, August 12th. Leerink Partnrs analyst F. Khurshid expects that the biopharmaceutical company will post earnings per share of ($0.03) for the quarter. The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron's Q2 2026 earnings at ($0.02) EPS and Q4 2026 earnings at $0.00 EPS.

Geron (NASDAQ:GERN - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.01. The company had revenue of $49.04 million during the quarter, compared to the consensus estimate of $47.30 million. Geron had a negative net margin of 53.52% and a negative return on equity of 31.37%. The firm's quarterly revenue was up 5455.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.10) earnings per share.

GERN has been the topic of a number of other research reports. The Goldman Sachs Group began coverage on Geron in a research report on Thursday, July 10th. They issued a "sell" rating and a $1.00 price target on the stock. Scotiabank lowered shares of Geron from a "sector outperform" rating to a "sector perform" rating and decreased their target price for the company from $4.00 to $1.50 in a report on Thursday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $4.19.

Geron Price Performance

NASDAQ GERN traded down $0.0050 during midday trading on Thursday, hitting $1.4350. The company had a trading volume of 2,301,185 shares, compared to its average volume of 12,727,350. The firm has a 50-day moving average price of $1.37 and a 200-day moving average price of $1.59. The company has a market capitalization of $915.56 million, a PE ratio of -10.96 and a beta of 0.73. The company has a current ratio of 7.87, a quick ratio of 6.79 and a debt-to-equity ratio of 0.46. Geron has a twelve month low of $1.09 and a twelve month high of $4.8250.

Institutional Investors Weigh In On Geron

A number of hedge funds and other institutional investors have recently bought and sold shares of GERN. Tower Research Capital LLC TRC raised its position in Geron by 551.4% in the second quarter. Tower Research Capital LLC TRC now owns 78,317 shares of the biopharmaceutical company's stock valued at $110,000 after purchasing an additional 66,294 shares during the last quarter. Exome Asset Management LLC raised its holdings in Geron by 6.2% in the 2nd quarter. Exome Asset Management LLC now owns 3,414,377 shares of the biopharmaceutical company's stock valued at $4,814,000 after buying an additional 198,920 shares during the last quarter. E Fund Management Co. Ltd. raised its holdings in Geron by 12.0% in the 2nd quarter. E Fund Management Co. Ltd. now owns 92,238 shares of the biopharmaceutical company's stock valued at $130,000 after buying an additional 9,849 shares during the last quarter. Soleus Capital Management L.P. boosted its position in Geron by 572.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 16,140,000 shares of the biopharmaceutical company's stock worth $22,757,000 after buying an additional 13,740,000 shares during the period. Finally, Vestal Point Capital LP increased its position in Geron by 8.0% in the 2nd quarter. Vestal Point Capital LP now owns 23,775,000 shares of the biopharmaceutical company's stock valued at $33,523,000 after acquiring an additional 1,769,660 shares during the period. Institutional investors own 73.71% of the company's stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.